Biotech Values

[walldiver]

<<5) This abstract reminds me of what has always made me nervous about Provenge---the fact that the vaccine is based on PAP, not a very specific and far from ideal prostate cancer antigen.>>

Are you sure about that? From what DNDN says, PAP is found in approx 95% of prostate cancers, and the only healthy tissue in which it's marked is prostate tissue. As Provenge is designed for patients who have had their prostates removed, to me it seems to be an ideal target.